Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Wellbeing Digital

KONEFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.000001

At close: Feb 9, 9:26 AM EDT

$0.00770

0.00770769900.00%

After Hours: Feb 9, 9:26 AM EDT

Wellbeing Digital (KONEF) Forecast

News

Earnings Wellbeing Digital (KONEF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Wellbeing Digital (OTC:KONEF) Stock

Wellbeing Digital Stock (OTC: KONEF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, June 26, 2023

World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees
Lara Goldstein

Monday, March 13, 2023

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Lara Goldstein

Thursday, March 09, 2023

Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
Lara Goldstein

Wednesday, March 08, 2023

Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
Lara Goldstein

Tuesday, February 21, 2023

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein

Tuesday, February 14, 2023

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Lara Goldstein

Monday, January 30, 2023

Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
Lara Goldstein

Tuesday, December 27, 2022

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
Lara Goldstein

Tuesday, December 06, 2022

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein

Thursday, December 01, 2022

EXCLUSIVE: MAPS To Host Major Psychedelics Event In 2023, Speakers & Details Below
Lara Goldstein

Wednesday, November 30, 2022

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Lara Goldstein

Tuesday, November 22, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein

Thursday, November 17, 2022

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Lara Goldstein

Tuesday, November 15, 2022

Successful Study On Transdermal CBD & THC Delivery Presents Benefits For Treating Chronic Conditions
Joana Scopel

Tuesday, November 01, 2022

Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant's LSD Therapy & More
Lara Goldstein

Thursday, October 27, 2022

Pathway Health To Acquire IRP Health From Wellbeing Digital Sciences
Vuk Zdinjak

Friday, October 07, 2022

Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Lara Goldstein

Wednesday, October 05, 2022

Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Lara Goldstein

Friday, September 16, 2022

Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong
Lara Goldstein

Tuesday, August 30, 2022

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
Lara Goldstein

Thursday, July 21, 2022

KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
Lara Goldstein

Monday, July 18, 2022

Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics
Lara Goldstein

Friday, March 18, 2022

Wellbeing Digital Net Loss Continues To Grow: Q2 Reaches $5.15M, Up By 552% YoY
Vuk Zdinjak

Tuesday, March 15, 2022

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
Benzinga Insights

Monday, March 14, 2022

Wellbeing Digital, Small Pharma Among Top Psychedelic Movers Of Today
Benzinga Insights

Monday, March 07, 2022

Psychedelic Stock Gainers And Losers From March 7, 2022
Benzinga Insights

Friday, March 04, 2022

Psychedelic Stock Gainers And Losers From March 4, 2022
Benzinga Insights

Tuesday, March 01, 2022

Psychedelic Stock Gainers And Losers From March 1, 2022
Benzinga Insights

Monday, February 28, 2022

Psychedelic Stock Gainers And Losers From February 28, 2022
Benzinga Insights

Monday, February 14, 2022

Psychedelic Stock Gainers And Losers From February 14, 2022
Benzinga Insights

Tuesday, February 08, 2022

Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
Rachael Green - Sponsored

Thursday, January 27, 2022

Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
Wellbeing Digital Sciences - Sponsored

Tuesday, January 18, 2022

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Natan Ponieman

Wednesday, January 12, 2022

Ketamine One Shares Uplisted To OTCQB
Aaron Bry

Wednesday, December 15, 2021

Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne
Jelena Martinovic

Friday, December 10, 2021

Cannabis Dispensary Roundup: Verano, Jushi, Cresco, KetamineOne
Jelena Martinovic

Monday, November 22, 2021

Cannabis Dispensary Roundup: Ascend Wellness, Ketamine One, Cresco, Kiaro, TILT, BELLEBUD
Jelena Martinovic

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Monday, September 27, 2021

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Natan Ponieman

Monday, August 30, 2021

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Natan Ponieman

Monday, August 23, 2021

KetamineOne Capital Forms Medical Advisory Board, Will Oversee Development Of Its Mental-Health Platform
Nina Zdinjak

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved